|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Distinct miRNAs have been demonstrated to be involved in the regulation of α-synuclein, a key player in PD pathogenesis; miR-153 and miR-223 are downregulated in the brain and serum of parkinsonian GFAP.HMOX1 transgenic mice where they directly regulate α-synuclein.
|
31800144 |
2020 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We conjecture that region-specific disparities in the susceptibility of dopaminergic and other circuitry to the trophic and degenerative influences of glial HMOX1 induction may permit the concomitant expression of mixed SCZ and PD traits within affected individuals.
|
31847534 |
2020 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HO-1 in stressed astroglia has previously been documented in the substantia nigra of idiopathic PD and may promote α-synuclein production and toxicity by downmodulating miR-153 and/or miR-223 both within the CNS and in peripheral tissues.
|
31180611 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The functional role of nuclear factor E2-related factor 2, Heme oxygenase-1, and selenium against ROS-dependent initiation and progression of PD is elucidated.
|
31153970 |
2019 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings point to HO-1 as a new therapeutic target linked to mitochondrial pathophysiology in Manganism and probably Parkinson´s disease.
|
30040983 |
2018 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.
|
29488275 |
2018 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that CO released by CORM-2 treatment may have protective effects against oxidative cell death in PD through the potentiation of cellular adaptive survival responses via activation of Nrf2 and upregulation of heme oxygenase-1, leading to increasing antioxidant defense capacity.
|
29429149 |
2018 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We genotyped the single-nucleotide polymorphisms (SNPs) rs2071746 and rs2071747 in HMOX1 and rs1051308 in HMOX2 in 583 Han Chinese with PD and 627 healthy controls using a customized 2×48-Plex SNP Scan™ kit.
|
28179208 |
2017 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several reports suggested a role of heme oxygenase genes 1 and 2 (HMOX1 and HMOX2) in modifying the risk to develop Parkinson disease (PD).
|
26091465 |
2015 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Induction of the glial HMOX1 gene may lead to pathological brain iron deposition, intracellular oxidative damage, and bioenergetic failure in AD and other human CNS disorders such as PD and MS.
|
25111043 |
2014 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of Nrf2/HO-1 leads to more α-syn aggregation and greater toxicity induced by iron, creating a vicious cycle of iron accumulation, α-syn aggregation and HO-1 disruption in PD.
|
23454680 |
2013 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results indicate a novel pathway by which the P209A defect in the PINK1 kinase domain inhibits oxidative stress-induced HO-1 and SOD2 induction, which may accelerate the neurodegeneration in PD with PINK1 defect.
|
23261939 |
2013 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Postmortem brain tissue samples from patients in early- to middle-stage progression of PD showed increased HO-1 expression in astrocytes and microglia, suggesting an attempt of the diseased brain to compensate these hallmarks of PD through activation of the Nrf2 pathway.
|
22513881 |
2012 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Functional polymorphisms in Hmox1 have been associated with high risk for Alzheimer's and Parkinson's disease.
|
20704549 |
2010 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Subjects carrying both the HO-1 (-413, rs2071746) TT genotype and the GSK3beta (-157, rs6438552) TT genotype had a four times higher risk of developing PD than subjects without these genotypes (adjusted by age and sex OR = 4.12; 95% CI = 1.45-11.71; Bonferroni corrected P = 0.024).
|
20039940 |
2010 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The increase of serum HO-1 levels in PD patients could indicate a systemic antioxidant reaction related to a chronic oxidative stress state in PD brain.
|
19785642 |
2010 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast to the effect on alpha-synuclein [wild-type (WT)] levels, HO-1 over-expression did not significantly impact PD-associated alpha-synuclein (A30P) levels in these cells.
|
19457084 |
2009 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, our analyses did not reveal a significant association of these genetic markers in the HO-1 gene with an increased susceptibility to PD.
|
19475336 |
2009 |
|
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
In PD brain, overexpression of HO-1 in nigral astroglia and accompanying iron liberation may facilitate the bioactivation of dopamine to neurotoxic free radical intermediates and predispose nearby neuronal constituents to oxidative damage.
|
17526019 |
2007 |
|
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Table 1 Biochemical Alterations in Substantia Nigra of Parkinson's Disease Indicating Oxidative Stress Elevated Decreased Iron (in microglia, astrocytes, oligodendrocytes, and melanized dopamine neurons and mitochondria) GSH (GSSG unchanged); GSH/GSSG ratio decreased Mitochondrial complex I Ferritin Calcium binding protein (calbindin 28) Mitochondrial monoamine oxidase B Transferrin and transferrin receptor Lipofuscin Vitamins E and C Ubiquitin Copper Cu/Zn-superoxide dismutase Cytotoxic cytokines (TNF-a, IL-1, IL-6) Inflammatory transcription factor NFKB Heme oxygenase-1 Ratio of oxidized to reduced glutathione (GSSG/GSH) Nitric oxide Neuromelanin.
|
21318773 |
2001 |
|
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that a (GT)n repeat in the human HO-1 gene promoter region is highly polymorphic, although no particular alleles are associated with AD or PD.
|
9225984 |
1997 |